Status:
UNKNOWN
Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Prostate Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The development of a personalized therapeutic education program dedicated to patients with metastatic prostate cancer and receiving next-generation hormone therapy would improve their knowledge of the...
Eligibility Criteria
Inclusion
- Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months
- The patient must have given their free and informed consent and signed the consent form
- The patient must be insured or the beneficiary of an insurance policy
Exclusion
- The subject is not in a fit state to express their consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
Key Trial Info
Start Date :
September 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04048252
Start Date
September 10 2019
End Date
December 1 2023
Last Update
September 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nimes
Nîmes, France, 30029